Under the Compounding Quality Act, which statement about 503A pharmacies is true?

Under the Compounding Quality Act, which statement about 503A pharmacies is true?

• A. They compound in response to individual prescriptions
• B. They compound in bulk
• C. They are not allowed to compound sterile products
• D. They are required to file quarterly reports

Answer: (A)

Traditional 503A compounding pharmacies are designed to fulfill specific patient prescriptions, creating medications tailored to an individual’s needs. That focus on patient-specific prescriptions is what makes this statement true: they compound in response to individual prescriptions. They do not compound in bulk; bulk manufacturing is the realm of 503B outsourcing facilities that produce larger quantities for broader distribution. They can compound sterile products for individual patients under prescription, so saying they’re not allowed to compound sterile products isn’t correct. Quarterly reporting is not a requirement for 503A pharmacies; that type of reporting is associated with 503B outsourcing facilities, which operate under different regulatory obligations.

Traditional 503A compounding pharmacies are designed to fulfill specific patient prescriptions, creating medications tailored to an individual’s needs. That focus on patient-specific prescriptions is what makes this statement true: they compound in response to individual prescriptions. They do not compound in bulk; bulk manufacturing is the realm of 503B outsourcing facilities that produce larger quantities for broader distribution. They can compound sterile products for individual patients under prescription, so saying they’re not allowed to compound sterile products isn’t correct. Quarterly reporting is not a requirement for 503A pharmacies; that type of reporting is associated with 503B outsourcing facilities, which operate under different regulatory obligations.